IN2014DN05759A - - Google Patents

Info

Publication number
IN2014DN05759A
IN2014DN05759A IN5759DEN2014A IN2014DN05759A IN 2014DN05759 A IN2014DN05759 A IN 2014DN05759A IN 5759DEN2014 A IN5759DEN2014 A IN 5759DEN2014A IN 2014DN05759 A IN2014DN05759 A IN 2014DN05759A
Authority
IN
India
Prior art keywords
control
basification
hcv
viral
formation
Prior art date
Application number
Inventor
Mathias Braun
Carl Alan Busacca
feng jing Chen
Edwin Louis Gump
Jenness B Majeska
Scott Pennino
Fenghe Qiu
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN05759(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IN2014DN05759A publication Critical patent/IN2014DN05759A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control moisture control excipient control capsule shell control basification and a reconstitution approach.
IN5759DEN2014 2012-01-12 2013-01-10 IN2014DN05759A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12
PCT/US2013/020934 WO2013106506A1 (en) 2012-01-12 2013-01-10 Stabilized pharmaceutical formulations of a potent hcv inhibitor

Publications (1)

Publication Number Publication Date
IN2014DN05759A true IN2014DN05759A (en) 2015-04-10

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5759DEN2014 IN2014DN05759A (en) 2012-01-12 2013-01-10

Country Status (27)

Country Link
US (2) US20140037719A1 (en)
EP (1) EP2802313A1 (en)
JP (1) JP2015503616A (en)
KR (1) KR20140109433A (en)
CN (1) CN104244926A (en)
AP (1) AP2014007760A0 (en)
AR (1) AR089710A1 (en)
AU (1) AU2013208024A1 (en)
BR (1) BR112014017058A8 (en)
CA (1) CA2861041A1 (en)
CL (1) CL2014001783A1 (en)
CO (1) CO7000774A2 (en)
EA (1) EA201400808A1 (en)
EC (1) ECSP14013104A (en)
HK (1) HK1204982A1 (en)
IL (1) IL233550A0 (en)
IN (1) IN2014DN05759A (en)
MA (1) MA35865B1 (en)
MX (1) MX2014008205A (en)
NZ (1) NZ626353A (en)
PE (1) PE20141817A1 (en)
PH (1) PH12014501598A1 (en)
SG (1) SG11201404042VA (en)
TN (1) TN2014000295A1 (en)
TW (1) TW201340969A (en)
UY (1) UY34569A (en)
WO (1) WO2013106506A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (en) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Inhibitors of hepatitis c virus
CN105073758B (en) 2013-03-15 2017-08-11 吉利德科学公司 Hepatitis c virus inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (en) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma CRYSTAL PHASES OF A POWERFUL HCV INHIBITOR
DE602004010137T2 (en) 2003-05-21 2008-09-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg COMPOUNDS AS HEPATITIS C INHIBITORS
JP5156374B2 (en) 2004-05-25 2013-03-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for preparing acyclic HCV protease inhibitor
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
EP2331538B1 (en) 2008-09-16 2014-04-16 Boehringer Ingelheim International GmbH Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hcv inhibitor
JP5553839B2 (en) 2008-11-21 2014-07-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition having potent HCV inhibitory activity for oral administration
JP5607736B2 (en) * 2009-07-07 2014-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for hepatitis C virus protease inhibitor

Also Published As

Publication number Publication date
ECSP14013104A (en) 2015-11-30
TN2014000295A1 (en) 2015-12-21
US20150190458A1 (en) 2015-07-09
BR112014017058A8 (en) 2017-07-04
JP2015503616A (en) 2015-02-02
BR112014017058A2 (en) 2017-06-13
EP2802313A1 (en) 2014-11-19
AP2014007760A0 (en) 2014-07-31
CA2861041A1 (en) 2013-07-18
CO7000774A2 (en) 2014-07-21
PH12014501598A1 (en) 2014-10-08
EA201400808A1 (en) 2015-02-27
UY34569A (en) 2013-07-31
SG11201404042VA (en) 2014-08-28
US20140037719A1 (en) 2014-02-06
IL233550A0 (en) 2014-08-31
AR089710A1 (en) 2014-09-10
AU2013208024A1 (en) 2014-07-10
WO2013106506A1 (en) 2013-07-18
CL2014001783A1 (en) 2014-12-12
PE20141817A1 (en) 2014-12-17
HK1204982A1 (en) 2015-12-11
MX2014008205A (en) 2014-08-08
TW201340969A (en) 2013-10-16
NZ626353A (en) 2016-02-26
KR20140109433A (en) 2014-09-15
MA35865B1 (en) 2014-12-01
CN104244926A (en) 2014-12-24

Similar Documents

Publication Publication Date Title
MX2018013668A (en) Inhibitors of hepatitis c virus.
FI3674298T3 (en) Substituted indazoles, process for their preparation, pharmaceutical formulations containing them, and their use for the preparation of medicaments
MX354516B (en) Vectors encoding rod-derived cone viability factor.
WO2012040389A3 (en) Substituted bicyclic hcv inhibitors
PL3313755T3 (en) Single-dose capsule for the preparation of beverages
DK2801611T3 (en) MICRO-ORGANISM THAT CAN PRODUCT L-AMINO ACID AND PROCEDURE FOR PREPARING L-AMINO ACID USING THE SAME
HK1205743A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments 3--135(10)16-
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
MX2017000676A (en) High purity oritavancin and method of producing same.
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
MD20150053A2 (en) Co-micronisation product comprising ulipristal acetate
IN2014DN05759A (en)
MX358507B (en) Chimeric vaccine antigens against hepatitis c virus.
PL2679216T3 (en) Form of medicine for the modified release of betahistine
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
HK1243712A1 (en) Nucleotide derivatives which are hcv inhibitors for use in the treatment of hepatitis c
PL3244744T3 (en) Material for de-dusting granular enzyme preparations
SG11201610453SA (en) Compounds for inhibiting hepatitis c virus, pharmaceutical compositions and uses thereof
EP3065737A4 (en) Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form
IN2014MU00077A (en)
HUP1400084A2 (en) Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical composition containing them
HUP1300648A2 (en) Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
IN2014MU00076A (en)
MX2015003954A (en) Pharmaceutical composition of controlled release in three pulses dependent on betahistine ph.
MY185444A (en) Enterovirus 71 antiviral peptides